CBD for Inflammation India: Complete Clinical & Ayurvedic Guide

If you've been searching for CBD for inflammation India, you're not alone. Millions of Indians live with chronic inflammatory conditions — from rheumatoid arthritis and ankylosing spondylitis to inflammatory bowel disease, psoriasis, and neuroinflammation — often cycling through NSAIDs and corticosteroids that carry serious long-term side effects. Cannabidiol (CBD), derived from the Vijaya leaf recognised by AYUSH, is emerging as a scientifically-backed, Ayurvedic-compliant approach to inflammation management. This comprehensive guide explains how CBD oil and Vijaya extracts work against the root mechanisms of inflammation, what Indian clinical and regulatory frameworks say, and how to use them safely.

What is Chronic Inflammation? India's Hidden Health Crisis

Inflammation is the body's first-line immune response — a cascade of chemical signals that rush white blood cells to sites of infection or injury. Acute inflammation, like the redness around a wound, is protective and resolves within days. Chronic inflammation is the problem: a low-grade, persistent smouldering that continues long after the trigger has gone, silently damaging tissues over months and years.

India carries one of the highest burdens of inflammatory disease globally:

• Arthritis: Over 180 million Indians live with some form of arthritis — rheumatoid, osteoarthritis, psoriatic, or ankylosing spondylitis. That's more people than the entire population of Russia.
• Inflammatory bowel disease (IBD): The incidence of Crohn's disease and ulcerative colitis is rising sharply in urban India, driven by dietary changes and gut microbiome disruption.
• Type 2 diabetes: Increasingly recognised as an inflammatory disease; India has 101 million diabetics, more than any other country.
• Neuroinflammation: Linked to depression, Parkinson's disease, Alzheimer's, and post-COVID cognitive decline — a growing concern in India's ageing population.
• Skin inflammation: Psoriasis affects 2–3% of Indians; atopic dermatitis (eczema) is the leading paediatric skin condition.

Conventional treatments — non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and diclofenac, corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) — are effective but come with a heavy toll: GI bleeding, kidney damage, immunosuppression, and cardiovascular risk with long-term use. This is why Ayurvedic practitioners, integrative physicians, and patients alike are exploring Vijaya extract (medical cannabis) and CBD as complementary anti-inflammatory agents.

How CBD Fights Inflammation: The Endocannabinoid Science

To understand how CBD reduces inflammation, you need to understand the endocannabinoid system (ECS) — a molecular signalling network discovered in the 1990s that is now recognised as one of the master regulators of immune function, pain perception, and homeostasis.

The ECS comprises three components:

1. Endocannabinoids — lipid-based neurotransmitters produced on demand by your cells. The two primary endocannabinoids are anandamide (AEA) and 2-arachidonoylglycerol (2-AG).
2. Cannabinoid receptors — primarily CB1 (dense in the brain and CNS) and CB2 (primarily in immune cells, gut, liver, and peripheral tissues).
3. Enzymes — FAAH breaks down anandamide; MAGL breaks down 2-AG. CBD inhibits FAAH, raising anandamide levels naturally.

When inflammation occurs, immune cells (macrophages, microglia, T-cells) surge to the site. CB2 receptors on these immune cells are the key target for CBD's anti-inflammatory action. CBD is not a direct CB2 agonist like THC — instead, it modulates CB2 signalling indirectly, reducing the pro-inflammatory activation cascade. Additionally, CBD acts on TRPV1 (vanilloid receptor), GPR55, and PPAR-γ — all of which play roles in pain and inflammation regulation.

CBD also inhibits the enzyme FAAH, slowing the breakdown of anandamide. Higher anandamide levels exert a "tonic" anti-inflammatory effect — suppressing unnecessary immune activation. This is one reason what is Vijaya extract has become such a critical question for patients with chronic inflammation: the plant's cannabinoids interact with a system your body already uses to self-regulate.

CB2 Receptors — Your Body's Built-in Anti-Inflammatory System

CB2 receptors are the primary target of interest when it comes to CBD for inflammation India and globally. Unlike CB1 receptors (which mediate the psychoactive effects of THC in the brain), CB2 receptors are predominantly expressed in immune tissues: lymph nodes, spleen, thymus, bone marrow, and circulating immune cells.

When activated, CB2 receptors:

• Suppress the production of pro-inflammatory cytokines — particularly TNF-α (tumour necrosis factor-alpha), IL-6 (interleukin-6), and IL-1β (interleukin-1 beta).
• Promote the shift from pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages.
• Reduce neutrophil infiltration at sites of acute inflammation, limiting collateral tissue damage.
• Modulate T-cell activity to reduce autoimmune over-activation.

This CB2-mediated mechanism is one reason CBD research has shown promise across such a wide range of inflammatory conditions — from joint inflammation to gut inflammation and neuroinflammation. It doesn't suppress the immune system wholesale (as corticosteroids do); it recalibrates immune cell behaviour toward resolution rather than escalation.

For patients in India using CBD products from licensed brands, this science translates to real-world benefit: reduced morning stiffness in arthritis, improved gut symptom scores in IBD, and reduced inflammatory skin lesions in psoriasis and eczema — all reported in clinical studies reviewed below.

NF-κB Pathway & Cytokine Suppression: What the Clinical Studies Say

The most important molecular target in chronic inflammation is the NF-κB (Nuclear Factor kappa B) pathway. NF-κB is a transcription factor that, when activated, switches on the genes encoding pro-inflammatory cytokines, adhesion molecules, and enzymes like COX-2 (the same enzyme NSAIDs inhibit). Chronic NF-κB activation is the central driver of most inflammatory diseases.

Clinical and pre-clinical research on CBD's anti-inflammatory effects has grown substantially:

Study 1: A comprehensive review by Boyaji et al. (2023), published on PubMed (PMID 37736946), examined both pre-clinical and clinical findings on CBD's anti-inflammatory effects. The review found positive results across all studies examining CBD in arthritis — including reduced synovial inflammation and cartilage preservation in animal models, and reduced inflammatory marker levels in human participants. The mechanism identified was consistent: CBD downregulates NF-κB activation and reduces downstream cytokine production.

Study 2: Nagarkatti et al. (2021), in a systematic review published on PubMed (PMID 33998900) of cannabinoids and cytokine modulation, found that in 22 out of the reviewed studies, administration of CBD (or CBD in combination with CBG) produced a measurable reduction in at least one major pro-inflammatory cytokine — primarily TNF-α, IL-6, or IL-1β. Twenty-four studies showed improvement in disease scores. The NF-κB suppression was identified as the common mechanism.

Study 3: Blasco-Benito et al. (2021), published on PubMed (PMID 34082108), found that CBD alone and in combination with CBG (cannabigerol) significantly reduced inflammatory cytokine levels through CB2-mediated immune modulation. The combination showed a synergistic "entourage effect" — a finding consistent with the Ayurvedic whole-plant extract philosophy behind Vijaya extract.

Study 4: Boyaji (2023), in a separate study on topical CBD (PMID 37669453), found that 1% topical CBD gel reduced oedema and arthritis markers in animal models, demonstrating that local (topical) anti-inflammatory action is mediated via CB2 receptors in skin and joint tissue — relevant for Indian patients exploring topical CBD for localised joint pain or skin inflammation.

Study 5: Piltonen et al. (2025), in a double-blind RCT tracking Parkinson's patients (CBD-PD-BRH trial, PMID 40267585), administered 26 mg/day sublingual CBD and measured inflammatory markers alongside motor and cognitive outcomes. CBD showed a safe profile with no adverse effects — supporting its use as a complementary anti-neuroinflammatory agent in progressive neurological conditions.

These studies together support the mechanism: CBD does not work like an NSAID (which chemically blocks COX enzymes) but acts upstream at the NF-κB and cytokine level — potentially addressing inflammation at a more fundamental biological level. If you want to discuss whether CBD is right for your specific inflammatory condition, our panel doctors can review your case and existing medications.

CBD vs NSAIDs — A Complete Comparison for Indian Patients

Many Indians take NSAIDs like ibuprofen (Brufen), naproxen, or diclofenac (Voveran) daily for inflammatory conditions. Understanding how CBD compares helps you and your doctor make an informed decision about integration or substitution.

Feature	NSAIDs (e.g., Ibuprofen, Diclofenac)	CBD / Vijaya Extract
Mechanism	COX-1/COX-2 enzyme inhibition	NF-κB suppression, CB2 modulation, cytokine reduction, FAAH inhibition
GI side effects	High — gastric ulcers, GI bleeding with chronic use	Low — may actually reduce gut inflammation
Kidney risk	Moderate-high with long-term use	Not reported at therapeutic doses
Cardiovascular risk	Elevated (especially COX-2 selective NSAIDs)	No clear cardiovascular risk; some cardioprotective signals
Onset of action	30–60 minutes (acute pain relief)	Days to weeks for chronic inflammatory conditions; minutes for sublingual dosing
Psychoactive effects	None	None (CBD is non-psychoactive)
Legal status in India	OTC/prescription drugs	AYUSH-licensed Vijaya extract; legal with valid prescription
Cost (India)	₹20–₹200 per strip (widely available)	₹849–₹7,021 per product (premium, longer-lasting)
Ayurvedic tradition	None	3,000+ years in classical Ayurvedic texts (Charaka Samhita)

Important: CBD and NSAIDs can be used complementarily. Consult our doctors before changing your existing medication regimen.

Vijaya Extract in Ayurvedic Medicine: 3,000 Years of Anti-Inflammatory Use

India has the world's oldest documented use of cannabis as an anti-inflammatory medicine. Long before "CBD" or "NF-κB" were terms in any pharmacology textbook, Ayurvedic physicians were prescribing Vijaya (cannabis) for inflammatory conditions:

• Charaka Samhita (~1st century BCE): Documents Vijaya as a treatment for pain, digestive disorders, and vatavyadhi — disorders of the Vata dosha, which maps broadly onto neurological and inflammatory conditions in modern terms.
• Sushruta Samhita: Describes cannabis leaf preparations for surgical wound inflammation and as an antinociceptive (pain-reducing) agent.
• Ashtanga Hridayam: References Vijaya as "Madakari" (mood-altering) and "Vedanasthapana" (pain-stabilising) — used in formulations for inflammatory joint diseases.

This historical context is not just cultural heritage — it forms the regulatory foundation for CBD's legal status in India. The Ministry of AYUSH's 2018 notification formally permitted the use of cannabis (as Vijaya) in Ayurvedic, Siddha, and Unani medicines. Under this framework, CBD products derived from cannabis leaves are classified under Schedule E-1 drugs — legal for manufacture, sale, and consumption when formulated by AYUSH-licensed manufacturers.

Modern brands like those available on THC Store's health & wellness collection bridge this Ayurvedic tradition with contemporary extraction technology — delivering standardised CBD concentrations in formats (oils, tinctures, capsules) that allow precise dosing while maintaining the Vijaya leaf extract regulatory framework. This makes India's approach to CBD oil for pain and inflammation unique globally: a 3,000-year-old herb, newly validated by molecular biology, now available through a modern e-commerce platform.

Types of Inflammatory Conditions CBD May Help With in India

CBD's anti-inflammatory mechanism — CB2 modulation, NF-κB suppression, cytokine reduction — means it has potential relevance across many inflammatory conditions. Below, we explore the four most clinically-studied and patient-reported applications in the Indian context. Always remember: individual response varies, and medical supervision is strongly recommended for chronic inflammatory disease.

CBD for Arthritis & Joint Inflammation India

Arthritis is the most commonly reported use of CBD for inflammation globally, and India is no exception. Rheumatoid arthritis (RA) — an autoimmune inflammatory disease affecting 0.5–1% of Indians — involves the immune system attacking joint synovium, producing chronic pain, swelling, and progressive joint destruction.

The Vijaya extract's CB2-rich activity makes it particularly interesting for RA and osteoarthritis (OA). CB2 receptors are expressed in synovial tissue, and activation reduces synovial inflammation and pannus formation. The Boyaji 2023 review found positive results across all arthritis studies, with CBD reducing both pain scores and inflammatory biomarkers (CRP, ESR).

For Indian patients, the practical approach combines:

• Internal CBD oil: Full-spectrum CBD oils taken sublingually (under the tongue) for systemic CB2 activation. Products like the Pain Relief Full Spectrum CBD Oil (₹2,549) are formulated specifically for aches and inflammation.
• Topical CBD: Applied directly to affected joints for localised CB2 activation — effective for knee OA, hand arthritis, and shoulder inflammation based on the Boyaji 2023 topical study.
• Vijaya extract tinctures: For moderate-to-severe RA patients, prescription Vijaya extracts with balanced THC:CBD ratios may offer superior anti-inflammatory action via both CB1 and CB2 pathways, though these require a doctor's prescription.

Before combining CBD with your existing arthritis medications (methotrexate, sulfasalazine, hydroxychloroquine), always consult your rheumatologist or our panel of cannabis-trained doctors. CBD can affect the metabolism of certain DMARDs via liver CYP450 enzymes.

CBD for Gut Inflammation (IBS, IBD, Colitis) India

The gut is one of the richest repositories of CB2 receptors in the human body — expressed densely in intestinal epithelial cells, enteric nervous system neurons, and gut-associated immune cells. This makes CBD for gut inflammation a particularly well-founded application.

In inflammatory bowel disease (Crohn's disease, ulcerative colitis), dysregulated immune activation in the gut wall leads to chronic ulceration, bleeding, and malabsorption. CB2 receptor activation by CBD:

• Reduces intestinal epithelial permeability ("leaky gut")
• Suppresses inflammatory cytokines from gut-associated macrophages
• Modulates mast cell activity and IgE response
• Reduces visceral hypersensitivity (the gut hypersensitivity characteristic of IBS)

Indian patients with IBD are increasingly turning to CBD oil as an adjunct to their conventional therapies (mesalazine, azathioprine, biologics). While CBD should never replace prescribed IBD medications, evidence suggests it may help maintain remission and reduce flare frequency. Book a consultation with our gastroenterology-aware panel doctors to discuss integrating CBD into your IBD management plan.

CBD for Neuroinflammation India

Neuroinflammation — inflammation within the brain and central nervous system — is now recognised as a driver of depression, anxiety disorders, Alzheimer's disease, Parkinson's disease, and post-COVID cognitive syndrome ("brain fog").

Microglia are the brain's resident immune cells; when chronically activated, they produce pro-inflammatory cytokines (IL-1β, TNF-α) that damage neurons. CBD's ability to modulate microglial activation through CB2 receptors (which are expressed in activated microglia) makes it a candidate neuroprotective agent.

The Piltonen 2025 CBD-PD-BRH trial (PMID 40267585) specifically examined CBD's effect on neuroinflammatory markers in Parkinson's patients — 26 mg/day sublingual CBD was safe and well-tolerated, with ongoing tracking of inflammatory biomarkers alongside motor function. This is meaningful for the estimated 580,000 Indians living with Parkinson's disease.

For Indians experiencing post-COVID cognitive symptoms, neurological burnout, or early cognitive decline, CBD's neuroprotective and anti-inflammatory properties may offer complementary support. Discuss neuroinflammatory applications with a specialist — our doctor consultation service can connect you with cannabis-literate physicians who understand both Ayurvedic and neuroscience frameworks.

CBD for Skin Inflammation — Eczema, Psoriasis & Acne India

India's tropical climate and high pollution load make inflammatory skin conditions extremely common. Psoriasis — an autoimmune inflammatory skin disease — affects 2–3% of the population. Atopic dermatitis (eczema) is the leading chronic skin condition in children. Cystic acne, mediated partly by sebaceous inflammation, affects millions of young adults.

The skin is uniquely rich in CB2 receptors, particularly in:

• Keratinocytes (skin cells)
• Sebaceous glands (relevant to acne)
• Mast cells (relevant to eczema and allergic skin reactions)
• Immune cells in the dermis

Topical CBD interacts with these receptors locally, without systemic absorption. The anti-inflammatory effects include reduced keratinocyte proliferation (slowing psoriatic plaque formation), reduced mast cell degranulation (reducing eczema itch and flare), and suppression of sebocyte lipid production and pro-inflammatory cytokines (reducing acne).

Hemp seed oil, which is different from CBD oil but contains its own anti-inflammatory omega-6 GLA (gamma-linolenic acid), has been used in Indian Ayurvedic skin care for centuries. CBD-enriched hemp products available at THC Store combine both benefits — the omega fatty acid base of hemp oil with the receptor-active anti-inflammatory power of CBD extract.

CBD Dosage for Inflammation in India — Practical Guide

There is no single "correct" dose of CBD for inflammation — individual response depends on body weight, metabolic rate, the severity and type of inflammation, the product's bioavailability format, and whether it's used alongside other medications. However, the clinical literature and practitioner experience in India suggest the following general guidance:

Dosage by Administration Route

• Sublingual CBD oil (tincture): Start at 15–25 mg CBD once or twice daily. Hold under tongue for 60–90 seconds before swallowing. Effects begin within 15–30 minutes. This is the most bioavailable oral route (~20–35% absorption).
• Capsules/softgels: 25–50 mg CBD daily. Slower onset (1–2 hours) due to first-pass metabolism, but more consistent effect over the day.
• Topical CBD: Apply liberally to affected joint or skin area 2–3 times daily. No systemic dose concern; start with the lowest concentration available and escalate as needed.
• Full-spectrum Vijaya extract (prescription): Dosed by a licensed Ayurvedic or integrative physician based on your condition and cannabinoid ratios. Typically 0.5–2 mL tincture per dose, twice daily.

General Titration Protocol (Consult Your Doctor First)

• Week 1: 10–15 mg CBD/day (morning). Note sleep, pain levels, morning stiffness.
• Week 2: If tolerated well, increase to 25–30 mg/day (split AM/PM).
• Week 3–4: Assess inflammatory markers if possible (CRP, ESR). Titrate to 50 mg/day if needed for moderate-to-severe inflammation.
• Maintenance: Most patients find a stable dose between 20–75 mg/day for chronic inflammatory conditions.

CBD is generally well tolerated, but may cause mild dry mouth, drowsiness at higher doses, or transient diarrhoea in some users. Critically, CBD inhibits liver CYP3A4 and CYP2C9 enzymes — meaning it can increase blood levels of certain drugs (blood thinners like warfarin, some antiepileptics, immunosuppressants). Always disclose CBD use to your prescribing doctor and consider checking with our cannabis medicine panel for a personalised dosing plan.

Best CBD Products for Inflammation Available in India

THC Store carries a curated range of AYUSH-compliant, third-party tested CBD and Vijaya extract products specifically beneficial for inflammatory conditions. Here are the top choices available at our oils collection:

• Pain Relief – Full Spectrum CBD Oil (For Aches & Inflammation) — ₹2,549: One of the most directly inflammation-targeted products in our range. Full-spectrum format preserves the entourage effect (all cannabinoids and terpenes working together), which research suggests is superior to CBD isolate for inflammatory applications.
• Pain Aid Tincture (For Inflammation and Pain Relief) — ₹2,799: A concentrated tincture formulated explicitly for inflammation and pain. Suitable for arthritis, joint inflammation, and fibromyalgia.
• Pain Relief – Natural Orange Flavor CBD Oil (The Trost) — ₹2,549: Palatable daily-use CBD oil from The Trost brand, a clinically-oriented hemp brand with a strong reputation in the Indian market for pain and inflammation formulations.
• Vanilla Flavor CBD Oil – For Chronic & Severe Pain — ₹1,444: Budget-friendly entry point for systemic CBD anti-inflammatory therapy. Ideal for patients starting out.
• BROAD SPECTRUM CBD Oil 5000 MG (Hemp Hub) — ₹7,021: High-potency option for severe chronic inflammatory conditions. Broad-spectrum removes THC while retaining other beneficial cannabinoids and terpenes.
• Paarmi Pain Oil — ₹849: An Ayurvedic topical pain and inflammation oil. Ideal for localised joint inflammation, especially knee and hip osteoarthritis.
• Vijaya Amrit (4:1 CBD:THC) – Neuro & Immuno Protective — ₹865: A prescription-grade Vijaya extract with a 4:1 CBD:THC ratio. THC at this ratio enhances CB1-mediated pain relief while CBD's anti-inflammatory CB2 action predominates. Requires a doctor's prescription — our consultation service can issue one.

Legal Status of CBD for Inflammation in India (2026 Update)

Navigating the legal landscape for CBD for inflammation India can seem daunting, but the framework is clearer than many patients realise:

1. NDPS Act 1985: Cannabis flowers and resin (charas, hashish) are prohibited narcotics under the NDPS Act. However, the Act explicitly excludes cannabis leaves and seeds from the definition of a narcotic. Hemp-derived CBD products made from leaves (not flowers/resin) fall outside NDPS prohibition.
2. AYUSH Ministry 2018 Notification: The Ministry of AYUSH formally permitted the inclusion of cannabis (Vijaya) in Ayurvedic, Siddha, and Unani formulations. Products from AYUSH-licensed manufacturers using Vijaya leaf extract are Schedule E-1 drugs — legally available with an Ayurvedic practitioner's prescription.
3. State-level variance: Some states (Uttarakhand, Himachal Pradesh) have issued state-level hemp cultivation licences, while others remain more restrictive. Federal AYUSH licensing takes precedence for licensed manufacturers.
4. THC limit: Products must contain ≤0.3% THC (dry weight basis) to be classified as hemp-derived and fall under AYUSH regulation rather than NDPS prohibition.

All CBD products available on THC Store are sourced from AYUSH-licensed manufacturers, lab-tested for THC content, and accompanied by compliance documentation. If you need a prescription for Schedule E-1 CBD products, our online doctor consultation service connects you with registered Ayurvedic physicians who can issue valid prescriptions within 48 hours.

How to Get Started with CBD for Inflammation in India

If you're considering CBD as part of your inflammation management strategy, here's a practical step-by-step:

1. Consult first: Book a consultation with our panel doctors to discuss your diagnosis, current medications, and whether CBD is appropriate for your case.
2. Start low, go slow: Begin with the lowest effective dose (15–25 mg CBD/day sublingual) and titrate up over 2–3 weeks.
3. Track your response: Keep a simple symptom diary — rate pain (0–10), note morning stiffness duration, sleep quality, and any side effects.
4. Pair with anti-inflammatory lifestyle: CBD works best alongside a turmeric-rich Indian diet (curcumin is a natural NF-κB inhibitor), omega-3 fatty acids, adequate sleep, and stress management.
5. Monitor labs: If on DMARDs, check with your rheumatologist about monitoring CYP enzyme-mediated drug interactions.
6. Choose full-spectrum for chronic inflammation: Full-spectrum CBD oils offer the entourage effect that research suggests is superior for complex chronic inflammatory conditions.

Frequently Asked Questions: CBD for Inflammation India

Is CBD oil legal for treating inflammation in India in 2026?

Yes, CBD products derived from cannabis leaves and formulated by AYUSH-licensed manufacturers are legal in India under the Ministry of AYUSH's 2018 notification. They are classified as Schedule E-1 drugs, which means they require a prescription from a registered Ayurvedic practitioner. Many online platforms, including THC Store, offer online consultations with licensed physicians who can issue valid prescriptions. CBD products must contain ≤0.3% THC to fall within the hemp-derived AYUSH framework rather than NDPS prohibition.

How long does CBD take to reduce inflammation?

The timeline varies by condition type and severity. For acute localised inflammation (joint flare, skin rash), topical CBD may provide relief within 30–60 minutes. For chronic systemic inflammation — arthritis, IBD, neuroinflammation — most patients report noticeable improvement after 2–4 weeks of consistent daily sublingual CBD use. Maximum benefit for chronic inflammatory conditions typically emerges at 6–8 weeks of therapeutic dosing. Unlike NSAIDs (which block pain acutely within hours), CBD works through a slower but potentially more sustained mechanism of immune modulation.

What's the difference between CBD oil and topical CBD for inflammation?

Sublingual CBD oil is absorbed directly into the bloodstream via mucous membranes under the tongue, providing systemic anti-inflammatory effects throughout the body — beneficial for arthritis affecting multiple joints, IBD, neuroinflammation, and widespread inflammatory conditions. Topical CBD (creams, roll-ons, oils applied to skin) acts locally at the site of application, interacting with CB2 receptors in skin, joint tissue, and subcutaneous immune cells without entering systemic circulation. Topicals are ideal for single-joint arthritis, skin inflammation, and localised pain. For maximum benefit in moderate-to-severe inflammatory disease, most practitioners recommend combining both approaches — sublingual for systemic effect and topical for targeted relief. See our full range of CBD oils and topicals.

Can I use CBD for inflammation if I'm already on NSAIDs or steroids?

Many patients combine CBD with their existing anti-inflammatory medications under medical supervision. CBD and NSAIDs can be complementary — CBD's upstream NF-κB mechanism and NSAID's COX enzyme inhibition target different parts of the inflammatory cascade, potentially offering additive benefit. However, CBD inhibits CYP450 liver enzymes (CYP3A4, CYP2C9) which metabolise many drugs including warfarin, some NSAIDs, and immunosuppressants. This can raise blood levels of these drugs. Always disclose CBD use to your prescribing doctor, and consider booking a specialist consultation through our platform before combining CBD with prescription medications.

Does CBD affect inflammatory blood markers like CRP and ESR?

Pre-clinical evidence strongly suggests CBD reduces markers of systemic inflammation including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and interleukin-6 (IL-6). The systematic review by Nagarkatti et al. (2021) found reductions in TNF-α, IL-6, and IL-1β across 22 of the reviewed studies. Human clinical trials on inflammatory markers are still accumulating — the Piltonen 2025 Parkinson's trial specifically tracked inflammatory markers alongside CBD treatment. While results are promising, CBD should be viewed as a complementary agent rather than a replacement for disease-modifying drugs in conditions like RA where ongoing CRP/ESR monitoring guides therapy. Ask your doctor to include inflammatory marker checks in your next blood panel while on CBD — it will help establish your personal response baseline.

The Ayurvedic Advantage: Why India Is Uniquely Positioned for CBD Anti-Inflammatory Therapy

India has a structural advantage that most countries lack: a 3,000-year tradition of plant-based medicine, a Ministry of AYUSH actively integrating cannabinoid medicine into its regulatory framework, and a population deeply culturally attuned to the concept of Prakriti (individual constitution) and Vikruti (imbalance/disease) — conceptual frameworks that map naturally onto personalised CBD dosing protocols.

The NF-κB signalling pathway suppressed by CBD is the same pathway that turmeric's curcumin (a cornerstone of Indian cooking and Ayurveda) also targets. This is not coincidence — both plants were selected over millennia for anti-inflammatory properties before the molecular biology was understood. Today, some integrative physicians are exploring curcumin-CBD combinations for synergistic anti-inflammatory effects, since the two compounds target overlapping but not identical inflammation pathways.

THC Store's vision — bringing Vijaya extract back into mainstream Indian healthcare through evidence-based, AYUSH-compliant formulations — is part of a broader reclamation of India's indigenous pharmacopoeia. If inflammation is at the root of what ails you, combining the molecular power of CBD with the systemic wisdom of Ayurvedic practice, supervised by a qualified physician, represents the most complete approach available in India today.

Ready to take the next step? Book a consultation with our panel doctors to discuss CBD for your specific inflammatory condition. Our physicians combine modern pharmacology with Ayurvedic expertise to design personalised protocols that work with — not against — your existing treatment plan.

Sources & References

1. Boyaji, S. et al. (2023). "Effects of Cannabidiol in Inflammation: A Review of Pre-clinical and Clinical Findings." PubMed. PMID: 37736946. Key finding: Positive results across all arthritis studies; CBD modulates NF-κB pathway and reduces pro-inflammatory cytokines.
2. Boyaji, S. (2023). "Analgesic and Anti-Inflammatory Effects of 1% Topical Cannabidiol Gel in Animal Models." PubMed. PMID: 37669453. Key finding: Topical CBD gel reduced oedema and arthritis markers via CB2 receptor pathways.
3. Piltonen, M. et al. (2025). "Cannabidiol and cognitive functions/inflammatory markers in Parkinson's disease: CBD-PD-BRH double-blind RCT." PubMed. PMID: 40267585. Key finding: 26 mg/day CBD safe and well-tolerated; inflammatory markers tracked alongside motor outcomes.
4. Nagarkatti, P. et al. (2021). "The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies." PubMed. PMID: 33998900. Key finding: CBD/CBG reduced TNF-α, IL-6, IL-1β in 22/reviewed studies; 24 studies showed disease improvement scores. NF-κB suppression identified as central mechanism.
5. Blasco-Benito, S. et al. (2021). "The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination." PubMed. PMID: 34082108. Key finding: CBD and CBG (in combination) significantly reduced inflammatory cytokine levels via CB2-mediated immune modulation — supporting whole-plant Vijaya extract formulations.